drugset
drugset / Trial / NCT04570956

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

NCT04570956 ↗

Phase 2 Terminated 65 enrolled Mayo Clinic National Cancer Institute (NCI) · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).

Timeline

Start
2021-07-26
Primary completion
2024-10-15
Completion
2024-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject 4-hydroxytamoxifen Unknown 4 mg Topical
Subject Tamoxifen Small molecule 10 mg Oral

Indications

atypical lobular breast hyperplasia lobular breast carcinoma in situ